Stage 4 Hodgkin's Lymphoma Prognosis

Also known as Hodgkin's disease, Hodgkin's lymphoma (HL) is a cancer of the white blood cells, or lymphocytes. Characterized by swelling in the lymph nodes, HL is most frequently treated with chemotherapy, especially in its later, more advanced stages.

Like many cancers, the spread of Hodgkin's lymphoma can be measured on a scale of four stages, with Stage I being least severe and Stage 4 being most. The following are characteristics of the four stages:

  • Stage 1 Hodgkin's Lymphoma: Stage I involves only a single lymph node, generally in the neck region, or one site outside the lymphatic system. It and Stage II can sometimes be treated with radiation therapy alone.
  • Stage 2 Hodgkin's Lymphoma: Stage II is the involvement of two or more nodes on the same side of the diaphragm.
  • Stage 3 Hodgkin's Lymphoma: Stage III has nodal involvement on both sides of the diaphragm, with possible involvement of the spleen.
  • Stage 4 Hodgkin's Lymphoma: Stage IV, the most serious phase of the disease, finds cancerous involvement of widespread extralymphatic organs (i.e., organs outside the system of lymph nodes).

There Are Options for Stage 4 Hodgkin's Lymphoma

While a diagnosis of Stage IV (Four) Hodgkin's lymphoma is a very serious diagnosis, HL remains one of the most treatable of cancers. It responds well to treatment, whether radiation or chemotherapy. About 60 percent of Stage IV patients will be cured of the disease.

Using the staging of the disease is not, however, always a reliable method of assessing survivability. An international effort in 1998 produced a list of seven factors that are intended to provide a more accurate measure of an individual person's likelihood of responding to treatment.

The scale is based on five-year freedom from progression (FFP), or the percentage of patients whose disease has been successfully halted within five years. Patients with zero factors have an 84 percent FFP. Each of the following factors reduces the 5-year FFP by seven percent:

  • Age greater than 44 years
  • Stage IV
  • Hemoglobin less than 10.5 g/dl
  • Lymphocyte count less than eight percent
  • Patient is male
  • Albumin less than 4.0 g/dl
  • White blood count of 15,000 per microlitre or higher

The reliability of the criteria declines with more than five factors, so for five or more factors, the 5-year FFP is said to be 42 percent.

The Hodgkin's lymphoma Stage IV prognosis is therefore reasonably positive. As one of the "best" cancers to have, Hodgkin's lymphoma is less likely to pose a threat to a patient's life, even in its more advanced stages, than many other diseases.

Photo: Pixabay

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap